prehensive, disease-state-oriented queries that disclose the quality and efficiency of the care and service. CareEvolve—Connectivity Solutions Through its CareEvolve subsidiary, the company offers a physician-based connectivity solution. This system provides a complex portal for ordering laboratory services and delivering laboratory results, along with ancillary connectivity services. Payors and Clients The company provides laboratory services to a range of healthcare providers, and to governmental agencies and large employer groups. Significant Events In 2012, the company entered into an agreement with Meridian Clinical Laboratory Corporation, a Florida corporation having its place of business in Miami, Florida (Meridian), pursuant to which the company purchased all issued and outstanding common stock of Meridian. In 2012, the company entered into an agreement with Florida Clinical Laboratory, Inc., a Florida corporation having its place of business in Melbourne, Florida (FCL). In August 7, 2013, the company purchased substantially all of the operating assets and certain of the operating liabilities of Hunter Laboratories, Inc. (Hunter) a California corporation having its principal place of business in Campbell, California. In August 20, 2013, the company through its subsidiary GeneDx, Inc. purchased the entire membership interest in Edge BioServ, LLC, (Edge Bio). Strategy The company seeks to continue its strong growth not only through marketing organization, new technologies and superior service. The principal components of strategy to achieve mission are as follows: capitalize on position within the clinical market; lead in providing medical information; provide the highest quality service; and pursue strategic growth opportunities, both through development of new testing services and through acquisitions. Regulations Waste Management, Health and Safety: The company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes. In New Jersey, the company is subject to the Comprehensive Medical Waste Management Act (CMWMA), which requires the company to register as a generator of special medical waste. The company is also subject to the Federal Hazardous Materials Transportation Law, 49 U.S.C. 5101 et seq., and the Hazardous Materials Regulations, or HMR, 49 CFR parts 171-180. Competition The company’s major competitors in the New York metropolitan area are two of the largest national laboratories, Quest Diagnostics (DGX) and Laboratory Corporation of America (LH). History Bio-Reference Laboratories, Inc. was founded in 1981.
bio-reference labs inc (BRLI:NASDAQ GS)
481 Edward H. Ross Drive
Elmwood Park, NJ 07407
|Alliance HealthCare Services Inc||$22.56 USD||-0.40|
|Genomic Health Inc||$32.71 USD||-1.05|
|Myriad Genetics Inc||$37.60 USD||+0.92|
|RadNet Inc||$8.86 USD||+0.28|
|Sequenom Inc||$3.04 USD||-0.235|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BIO-REFERENCE LABS INC, please visit www.bioreference.com. Company data is provided by Capital IQ. Please use this form to report any data issues.